Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06TWE
|
||||
| Former ID |
DIB013516
|
||||
| Drug Name |
CLX-0921
|
||||
| Synonyms |
CLX-090502; CLX-090503; CLX-090717; CLX-092402
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 1 | [526686] | ||
| Company |
Calyx Therapeutics Inc; Calyx Therapeutics
|
||||
| Canonical SMILES |
N1C(=O)SC(C1=O)Cc1ccc(Oc2ccc(/C(=C\c3cc(cc(c3)OC)OC)/C(<br />=O)OC)cc2)cc1
|
||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Agonist | [526686] | |
| PANTHER Pathway | CCKR signaling map ST | ||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.